Anti-mouse/human ADRA2A (Extracellular) Recombinant Monoclonal Antibody (XM0069)
Price range: $230.00 through $720.00
Anti-mouse/human ADRA2A Recombinant Monoclonal Antibody (XM0069) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library, followed by structure-guided affinity optimization. The antibody recognizes both mouse and human ADRA2A through a conserved epitope (AA 3–24) located within the N-terminal extracellular flexible region of alpha-2A adrenergic receptor (ADRA2A). It has been validated by ELISA using a recombinant epitope-Fc fusion antigen, by Western blot against a recombinant MBP-epitope fusion protein, by Western blot detection of endogenous ADRA2A protein in HEK293T cell lysates and mouse tissue lysates, and by immunofluorescence staining of mouse skeletal muscle tissue.
Also known as: hADRA2A, mADRA2A, ADRA2A, Alpha-2A adrenergic receptor, and ADRA2R.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-mouse/human ADRA2A Recombinant Monoclonal Antibody |
| Antibody ID | XM0069 |
| Target Protein | Alpha-2A adrenergic receptor |
| Target Protein Short Name | ADRA2A |
| UniProt Accession | Human: P08913; Mouse: Q01338 |
| Molecular Weight | Human: 50.6 kDa; Mouse: 50.6 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Mouse, Human |
| Tested Applications | WB, IF, ELISA |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | RQEQPLAEGSFAPMGSLQPDAG |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
ADRA2A (Alpha-2A adrenergic receptor) is a G protein-coupled receptor (GPCR) involved in adrenergic signaling and regulation of neurotransmitter release, cardiovascular activity, neuronal signaling, and sympathetic nervous system responses.
ADRA2A is widely studied in neuroscience, cardiovascular biology, GPCR signaling, neuropharmacology, hypertension research, psychiatric disorders, and receptor signaling pathways.
Antibody Development
XM0069 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the ADRA2A epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous full-length ADRA2A protein
- Immunofluorescence staining of endogenous mouse ADRA2A in skeletal muscle tissue
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length ADRA2A protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while no significant binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous full-length ADRA2A protein under reducing conditions.
Validated samples:
- eWAT tissue
- Brain tissue
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Major bands observed near expected molecular weight for endogenous ADRA2A protein
Immunofluorescence Validation
Immunofluorescence staining of mouse skeletal muscle tissue showed endogenous ADRA2A-associated signal using XM0069. ADRA2A signal is shown in green and nuclei are counterstained with DAPI (blue).
| Size | 20 ul, 100 ul |
|---|
Related products
